Correction: A randomized study of standard versus double dose oseltamivir for treating influenza in the community (Antiviral Therapy (2015) 20 (689–698) DOI: 10.3851/IMP2807);A randomized study of standard versus double dose oseltamivir for treating influenza in the community

Antiviral Therapy

Volumn 20, Issue 7, 2015, Pages 689-698

  Dixit, Rashmi ^a   Khandaker, Gulam ^a   Hay, Peter ^b   McPhie, Kenneth ^c   Taylor, Janette ^c   Rashid, Harunor ^a   Heron, Leon ^a   Dwyer, Dominic ^c   Booy, Robert ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b Castle Hill Medical Centre   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS STRAIN; VOMITING; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; DRUG ADMINISTRATION; DRUG EFFECTS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MIDDLE AGED; PATIENT COMPLIANCE; PRESCHOOL CHILD; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PATIENT COMPLIANCE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84973879796     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3276     Document Type: Erratum

References (59)

1. Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 2006; 4:795-805.
2. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007 - lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009; 14:19112.
3. Yang JR, Lin YC, Huang YP, et al. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009. PLoS ONE 2011; 6:e18177.
4. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-560.
5. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15:155-162.
6. Hurt AC, Deng YM, Ernest J, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill 2011; 16:19770.
7. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
8. WHO. Influenza-like illness in the United States and Mexico. (Updated 24 April 2009. Accessed 5 April 2013.) Available from http://www.who.int/csr/don/2009-04-24/en/index.html
9. WHO. Update on oseltamivir resistance in influenza A(H1N1)2009 viruses. (Accessed 5 April 2013.) Available from http://www.who.int/influenza/surveillance-monitoring/updates/2011-09-09-weekly-web-update-oseltamivir-resistance.pdf
10. Global monitoring of antiviral resistance in currently circulating human influenza viruses, November 2011. Wkly Epidemiol Rec 2011; 86:497-501.
11. WHO. Pandemic (H1N1) 2009 - update 67. (Updated 20 September 2009. Accessed 5 April 2013.) Available from http://www.who.int/csr/don/2009-09-25/en/index.html
12. WHO. Update on oseltamivir resistance to influenza H1N1 (2009) viruses. (Updated 12 January 2011. Accessed 5 April 2013.) Available from http://www.who.int/influenza/2011-01-12-weekly-web-update-oseltamivir-resistance.pdf
13. WHO. Pandemic (H1N1) 2009: antiviral drug resistance. (Updated 22 December 2009. Accessed 5 April 2013.) Available from http://www.who.int/csr/disease/swineflu/frequently-asked-questions/antivirals/resistance/en/index.html
14. Harvala H, Gunson R, Simmonds P, et al. The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. Euro Surveill 2010; 15:19536.
15. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068-1075.
16. Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J Antimicrob Chemother 2011; 66:466-470.
17. Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009; 69:2523-2531.
18. Jackson HC, Roberts N, Wang ZM, Belshe R. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Investig 2000; 20:447-454.
19. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765.
20. Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011; 52:432-437.
21. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133.
22. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55:i5-i21.
23. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 48:389-396.
24. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS ONE 2008; 3:e3410.
25. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011; 203:18-24.
26. Quach C, Newby D, Daoust G, Rubin E, McDonald J. QuickVue influenza test for rapid detection of influenza A and B viruses in a pediatric population. Clin Diagn Lab Immunol 2002; 9:925-926.
27. Quidel. QuickVue Influenza A+B test. (Accessed 30 November 2013.) Available from http://www.quidel.com/products/product-detail.php?prod=101&group=1
28. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis 2009; 48:e89-e92.
29. Rashid H, Shafi S, Haworth E, et al. Value of rapid testing for influenza among Hajj pilgrims. Travel Med Infect Dis 2007; 5:310-313.
30. Rouleau I, Charest H, Douville-Fradet M, Skowronski DM, De Serres G. Field performance of a rapid diagnostic test for influenza in an ambulatory setting. J Clin Microbiol 2009; 47:2699-2703.
31. CDC. Antiviral dosages: guidance on the use of influenza antiviral agents. (Accessed 7 July 2013.) Available from http://www.cdc.gov/flu/professionals/antivirals/antiviraldosage.htm
32. Wang B, Dwyer DE, Blyth CC, et al. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res 2010; 87:16-21.
33. Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148-157.
34. Wang B, Taylor J, Ratnamohan M, et al. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011. Euro Surveill 2012; 17:20210.
35. Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010; 15:19565.
36. Australian Government Department of Health. Australian influenza report 2012 - 29 September to 12 October 2012 (#10/2012). Canberra, Australian Government Department of Health and Ageing, 2012. (Accessed 5 April 2013.) Available from http://www.health.gov.au/internet/main/publishing.nsf/content/cda-surveil-ozflu-flucurr.htm.
37. Australian Government Department of Health. Pandemic (H1N1) 2009 influenza and oseltamivir resistance - 12 September 2011. Canberra, Australian Government Department of Health and Ageing, 2011. (Updated 6 October 2011. Accessed 5 April 2013.) Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-Influenza
38. WHO. Influenza update: 02 April 2013 - Update number 182. Geneva, World Health Organization, 2012. (Updated 2 April 2013. Accessed 5 April 2013.) Available from http://www.who.int/influenza/surveillance-monitoring/updates/latest-update-GIP-surveillance/en/index.html
39. WHO. Influenza - update 115. Geneva, WHO, 2010 (Updated 27 August 2010. Accessed 5 April 2013.) Available from http://www.who.int/csr/don/2010-08-27/en/index.html
40. WHO. Summary review of the 2010-2011 northern hemisphere winter influenza season. Geneva, World Health Organization, 2011. (Accessed 5 April 2013.) Available from http://www.who.int/influenza/surveillance-monitoring/2010-2011-GIP-surveillance-seasonal-review/en/index.html
41. WHO. Influenza laboratory surveillance information by the Global Influenza Surveillance and Response System (GISRS). Southern Hemisphere. 2013. (Updated 2 February 2013. Accessed 2 February 2013.) Available from http://gamapserver.who.int/gareports/Default.aspx?ReportNo=5&Hemisphere=Southern
42. WHO. Influenza laboratory surveillance information by the Global Influenza Surveillance and Response System (GISRS). Northern Hemisphere. 2013. (Updated 2 February 2013. Accessed 2 February 2013.) Available from http://gamapserver.who.int/gareports/Default.aspx?ReportNo=5&Hemisphere=Northern
43. Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Disord Drug Targets 2013; 13:34-45.
44. Farrar J, Sedyaningsih ER, Malik MS, Setiawaty V, et al. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.
45. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013; 57:1511-1519.
46. Santos L, Correia V, Giria M, et al. Genetic and antiviral drug susceptibility profiles of pandemic A (H1N1) influenza virus circulating in Portugal. Options for the Control of Influenza VII. 3-7 September 2010, Hong Kong SAR, China. Paper O-851.
47. Rousset D, Le Goff J, Abou-Jaoude G, et al. Emergence of successive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivir resistance and reduced susceptibility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors. Options for the Control of Influenza VII. 3-7 September 2010, Hong Kong SAR, China. Poster P-198.
48. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381-1382.
49. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010; 51:983-984.
50. Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011; 16:19884.
51. Hurt AC, Leang SK, Speers DJ, Barr IG, Maurer-Stroh S. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 2012; 18:109-112.
52. Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240-248.
53. Australian Government Department of Health and Aging. Australian Influenza Surveillance Report No. 13, 2011, reporting period: 3 September to 16 September 2011 Australian Government Department of Health and Ageing 2011. (Updated September 2011. Accessed 18 November 2012.) Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-ozflu-no13-11.htm/$file/ozflu-no13-2011.pdf
54. Takashita E, Ejima M, Itoh R et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Eurosurveill 2014; 19:20666.
55. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901-908.
56. Storms AD, Gubareva LV, Su S, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 2012; 18:308-311.
57. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024.
58. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5:205-213.
59. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-1246.